Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 10/20 | 0.33 |
| ▸ | GSK3B | P49841 | 10/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | FLT3 | P36888 | 9/20 | 0.33 |
| ▸ | JAK2 | O60674 | 6/20 | 0.32 |
| ▸ | SRC | P12931 | 6/20 | 0.32 |
| ▸ | PLK1 | P53350 | 5/20 | 0.32 |
| ▸ | PRKACA | P17612 | 5/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.32 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977698 | 0.83 | PIK3CG (0.35) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL18352778 | 0.81 | GRM4 (0.37) | — | |
| SCHEMBL22894098 | 0.79 | GSK3A (0.39) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL19250682 | 0.76 | SGK1 (0.33) | — | |
| SCHEMBL9977736 | 0.76 | GSK3A (0.35) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL18682878 | 0.73 | GSK3A (0.41) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL24929792 | 0.72 | GSK3A (0.45) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL9970800 | 0.71 | PIK3CG (0.32) | GSK3AGSK3BPIK3CGPIK3CAFLT3 | |
| SCHEMBL19250804 | 0.70 | NOS3 (0.33) | PIK3CA | |
| SCHEMBL9977673 | 0.70 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016005330-A1 | DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-14 | — | — | WO | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | MME, CAPRIN1, XPNPEP1 | GSK3A 395/4885GSK3B 304/4885PIK3CG 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.